|

Avelumab Clinical Trials

16 actively recruiting trials across 8 locations

Also known as: Anti-PD-L1, BAVENCIO, BAVENCIO®, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C

Other7 trials

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
Phase 2
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
Phase 2
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Phase 2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Phase 1
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Phase 2
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
Phase 1/2

Birmingham, Alabama2 trials

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

O'Neal Comprehensive Cancer Center

Phase 2
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Tucson, Arizona1 trial

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The University of Arizona Cancer Center-North Campus

Phase 2

Little Rock, Arkansas1 trial

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

University of Arkansas for Medical Sciences

Phase 2/3

Duarte, California1 trial

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

City of Hope Comprehensive Cancer Center

Phase 1/2

Washington D.C., District of Columbia1 trial

Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

Georgetown University

Phase 2

Miami, Florida1 trial

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Sylvester Comprehensive Cancer Center - Miami

Phase 1/2

Bethesda, Maryland1 trial

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

National Institutes of Health Clinical Center

Phase 2

Boston, Massachusetts1 trial

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Dana-Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.